WEE1 and neoplasm: Furthermore, it has been suggested that with optimised dose scheduling, combined PARP and WEE1 or ATR inhibition can enhance tumour killing with minimal systemic toxicity, owing to higher basal levels of replication stress in malignant versus normal tissue [34].